- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Federal Panel Scales Back MU Stage 3
Members of the Health IT Policy Committee approved a set of recommendations Tuesday that will bring meaningful use Stage 3 requirements one step closer to federal approval and scale back the initial Stage 3 proposals by 33%.
Members of the Health IT Policy Committee approved a set of recommendations Tuesday that will bring meaningful use Stage 3 requirements one step closer to federal approval and scale back the initial Stage 3 proposals by 33 percent.
Leaving 19 measures as part of the proposal, the recommendations, presented as a Stage 3 matrix developed by the meaningful use workgroup, will be sent on to Kathleen Sebelius, secretary of Health and Human Services for consideration in developing the final Stage 3 MU requirements. More public hearings and a notice of proposed rulemaking to inform HHS’s final requirements are expected to follow in 2015.
Read the full story here: http://bit.ly/Ptfs7h
Source: Healthcare IT News
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Optune Lua Device in NSCLC
October 16th 2024Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Read More
